AU2020272030C1 - Crystal forms of a pyridazinone TRPC inhibitor - Google Patents

Crystal forms of a pyridazinone TRPC inhibitor

Info

Publication number
AU2020272030C1
AU2020272030C1 AU2020272030A AU2020272030A AU2020272030C1 AU 2020272030 C1 AU2020272030 C1 AU 2020272030C1 AU 2020272030 A AU2020272030 A AU 2020272030A AU 2020272030 A AU2020272030 A AU 2020272030A AU 2020272030 C1 AU2020272030 C1 AU 2020272030C1
Authority
AU
Australia
Prior art keywords
crystalline form
ray powder
powder diffraction
angles
diffraction peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020272030A
Other languages
English (en)
Other versions
AU2020272030B2 (en
AU2020272030A1 (en
Inventor
Yuejun GAO
Wenfeng Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GFB (ABC) LLC
Original Assignee
GFB (ABC) LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GFB (ABC) LLC filed Critical GFB (ABC) LLC
Publication of AU2020272030A1 publication Critical patent/AU2020272030A1/en
Assigned to GFB (ABC), LLC reassignment GFB (ABC), LLC Request for Assignment Assignors: GOLDFINCH BIO, INC.
Application granted granted Critical
Publication of AU2020272030B2 publication Critical patent/AU2020272030B2/en
Priority to AU2026201003A priority Critical patent/AU2026201003A1/en
Publication of AU2020272030C1 publication Critical patent/AU2020272030C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU2020272030A 2019-04-10 2020-04-10 Crystal forms of a pyridazinone TRPC inhibitor Active AU2020272030C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201003A AU2026201003A1 (en) 2019-04-10 2026-02-11 Crystal forms of a pyridazinone TRPC inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2019/081985 WO2020206623A1 (en) 2019-04-10 2019-04-10 Crystal forms
AUPCT/CN2019/081985 2019-04-10
PCT/US2020/027689 WO2020210639A1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone trpc inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201003A Division AU2026201003A1 (en) 2019-04-10 2026-02-11 Crystal forms of a pyridazinone TRPC inhibitor

Publications (3)

Publication Number Publication Date
AU2020272030A1 AU2020272030A1 (en) 2021-11-11
AU2020272030B2 AU2020272030B2 (en) 2025-11-13
AU2020272030C1 true AU2020272030C1 (en) 2026-05-07

Family

ID=70482847

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020272030A Active AU2020272030C1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone TRPC inhibitor
AU2026201003A Pending AU2026201003A1 (en) 2019-04-10 2026-02-11 Crystal forms of a pyridazinone TRPC inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201003A Pending AU2026201003A1 (en) 2019-04-10 2026-02-11 Crystal forms of a pyridazinone TRPC inhibitor

Country Status (10)

Country Link
US (1) US12655132B2 (cg-RX-API-DMAC7.html)
EP (1) EP3953352A1 (cg-RX-API-DMAC7.html)
JP (2) JP7738482B2 (cg-RX-API-DMAC7.html)
CN (2) CN114502552B (cg-RX-API-DMAC7.html)
AU (2) AU2020272030C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018221A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136652A1 (cg-RX-API-DMAC7.html)
MA (1) MA55614A (cg-RX-API-DMAC7.html)
MX (2) MX2021012313A (cg-RX-API-DMAC7.html)
WO (2) WO2020206623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
LT3852533T (lt) * 2018-09-18 2024-06-10 Gfb (Abc), Llc Piridazinonai ir jų naudojimo būdai
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
CA3136632A1 (en) 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Gfb (Abc), Llc Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
KR102873922B1 (ko) 2020-07-03 2025-10-20 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도
JP7701559B2 (ja) * 2021-09-10 2025-07-01 メッドシャイン ディスカバリー インコーポレイテッド ハロゲン置換のピリダジノン系化合物及びその使用
EP4470540A4 (en) * 2022-01-27 2025-06-11 Wuhan Createrna Science and Technology Co.,Ltd. USE OF A HETEROCYCLIC COMPOUND
CN119546303A (zh) * 2022-08-05 2025-02-28 武汉朗来科技发展有限公司 包含杂环化合物的药物组合物及其制备方法和应用
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055966A2 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
LT3852533T (lt) 2018-09-18 2024-06-10 Gfb (Abc), Llc Piridazinonai ir jų naudojimo būdai
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
KR102873922B1 (ko) 2020-07-03 2025-10-20 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055966A2 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE

Also Published As

Publication number Publication date
JP7738482B2 (ja) 2025-09-12
EP3953352A1 (en) 2022-02-16
CA3136652A1 (en) 2020-10-15
WO2020206623A1 (en) 2020-10-15
BR112021018221A2 (pt) 2022-01-18
MX2021012313A (es) 2021-11-17
JP2022525759A (ja) 2022-05-19
MA55614A (fr) 2022-02-16
JP2026004294A (ja) 2026-01-14
MX2025006384A (es) 2025-07-01
US20220177455A1 (en) 2022-06-09
AU2020272030B2 (en) 2025-11-13
WO2020210639A1 (en) 2020-10-15
AU2026201003A1 (en) 2026-03-05
CN114502552A (zh) 2022-05-13
AU2020272030A1 (en) 2021-11-11
CN119264134A (zh) 2025-01-07
US12655132B2 (en) 2026-06-16
CN114502552B (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
AU2020272030B2 (en) Crystal forms of a pyridazinone TRPC inhibitor
JP6854766B2 (ja) チロシンキナーゼ阻害剤を用いる組成物および方法
CN114040913B (zh) 哒嗪酮trpc5抑制剂的喷雾干燥制剂
EP2651403B1 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
US20240091303A1 (en) Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
AU2019344928A1 (en) Pyridazinones and methods of use thereof
WO2026067059A1 (zh) Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途
JP2004534760A (ja) 腎線維症の治療
JP2930281B2 (ja) 皮膚疾患処置用薬剤
HK40122791A (en) Crystal forms of a pyridazinone trpc inhibitor
BR122025019562A2 (pt) Formas cristalinas de um inibidor de trpc de piridazinona, composição farmacêutica que as compreende e uso das mesmas
CN118043050A (zh) 用固体形式的比托哌汀治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
KR20190091621A (ko) 벤조[d]싸이아졸 유도체 또는 이의 염을 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물
BR122025019564A2 (pt) Dispersão seca por pulverização, composição para sua formulação e método de fabricação da mesma, forma de dosagem sólida e seu método de fabricação, e uso de um inibidor de piridazinona trpc5 para tratar dor, ansiedade ou depressão
TW200522962A (en) Neutrophilia inhibitor
OA19594A (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GFB (ABC), LLC

Free format text: FORMER APPLICANT(S): GOLDFINCH BIO, INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 FEB 2026

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 FEB 2026

FGA Letters patent sealed or granted (standard patent)